Magnus Halle - GH Research CoFounder Ireland
| GHRS Stock | USD 12.07 0.21 1.77% |
Insider
Magnus Halle is CoFounder Ireland of GH Research PLC
| Age | 27 |
| Address | Joshua Dawson House, Dublin, Ireland, D02 RY95 |
| Phone | 353 1 437 8334 |
| Web | https://www.ghres.com |
GH Research Management Efficiency
The company has return on total asset (ROA) of (0.1515) % which means that it has lost $0.1515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1958) %, meaning that it created substantial loss on money invested by shareholders. GH Research's management efficiency ratios could be used to measure how well GH Research manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2025. Return On Capital Employed is likely to drop to -0.18 in 2025. At this time, GH Research's Other Current Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0 in 2025, whereas Total Assets are likely to drop slightly above 175.1 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA MBA | Pharvaris BV | 63 | |
| Chulani Karunatilake | Werewolf Therapeutics | 65 | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| Charles Winter | Janux Therapeutics | 56 | |
| Kyle Breidenstine | PepGen | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Peng MD | Pharvaris BV | 47 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| CFA CPA | Janux Therapeutics | 45 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Michael MBA | Champions Oncology | N/A | |
| RA MSc | Pharvaris BV | 44 | |
| MD MBA | Rezolute | N/A | |
| MBA MD | Ikena Oncology | 59 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Joo MD | Design Therapeutics | 61 | |
| Sonia DPHIL | PepGen | 38 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Alfredo Castro | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 |
GH Research PLC Leadership Team
Elected by the shareholders, the GH Research's board of directors comprises two types of representatives: GH Research inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GHRS. The board's role is to monitor GH Research's management team and ensure that shareholders' interests are well served. GH Research's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GH Research's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie ACA, VP Fin | ||
| Magnus Halle, CoFounder Ireland | ||
| Naoise Gaffney, VP Property | ||
| Velichka MD, Chief Officer | ||
| Florian M, CoFounder Chairman | ||
| Theis MD, CoFounder CEO | ||
| Aaron MBA, Chief Officer | ||
| MSc MD, Chief Officer | ||
| Julie FCA, Vice Finance |
GHRS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GH Research a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 586.95 M | ||||
| Shares Outstanding | 62.03 M | ||||
| Shares Owned By Insiders | 33.87 % | ||||
| Shares Owned By Institutions | 52.11 % | ||||
| Number Of Shares Shorted | 2.87 M | ||||
| Price To Book | 4.11 X | ||||
| EBITDA | (50.18 M) | ||||
| Net Income | (38.96 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GHRS Stock Analysis
When running GH Research's price analysis, check to measure GH Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GH Research is operating at the current time. Most of GH Research's value examination focuses on studying past and present price action to predict the probability of GH Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GH Research's price. Additionally, you may evaluate how the addition of GH Research to your portfolios can decrease your overall portfolio volatility.